Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow disability progression.

Columnist Ben Hofmeister says he makes sure to ask questions in a healthcare setting because his experience as a patient is important.

A study found neurofilament light chain at high levels in the blood and CSF of MS patients, suggesting its potential as a ...